Total Payments
$1.1M
2024 Payments
$153,373
Companies
12
Transactions
672
Medicare Patients
181
Medicare Billing
$26,436
Payment Breakdown by Category
Consulting$473,750 (44.9%)
Other$402,125 (38.1%)
Travel$160,609 (15.2%)
Food & Beverage$12,466 (1.2%)
Research$7,150 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $473,750 | 91 | 44.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $378,081 | 132 | 35.8% |
| Travel and Lodging | $160,609 | 280 | 15.2% |
| Honoraria | $24,044 | 5 | 2.3% |
| Food and Beverage | $12,466 | 163 | 1.2% |
| Unspecified | $7,150 | 1 | 0.7% |
Payments by Type
General
$1.0M
671 transactions
Research
$7,150
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $521,396 | 324 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $416,742 | 202 | $0 (2024) |
| PORTOLA PHARMACEUTICALS, INC. | $75,787 | 83 | $0 (2019) |
| Gilead Sciences, Inc. | $22,819 | 30 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $9,175 | 8 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $3,920 | 14 | $0 (2023) |
| PFIZER S.A.S. | $3,213 | 1 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,666 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,171 | 3 | $0 (2023) |
| Johnson & Johnson Health Care Systems Inc. | $97.70 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $153,373 | 72 | PFIZER INC. ($86,365) |
| 2023 | $100,972 | 45 | E.R. Squibb & Sons, L.L.C. ($82,731) |
| 2022 | $106,443 | 34 | E.R. Squibb & Sons, L.L.C. ($54,042) |
| 2021 | $102,631 | 22 | E.R. Squibb & Sons, L.L.C. ($65,663) |
| 2020 | $81,854 | 37 | E.R. Squibb & Sons, L.L.C. ($45,256) |
| 2019 | $225,915 | 162 | PFIZER INC. ($174,743) |
| 2018 | $136,149 | 131 | PORTOLA PHARMACEUTICALS, INC. ($72,322) |
| 2017 | $148,763 | 169 | PFIZER INC. ($90,655) |
All Payment Transactions
672 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,220.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,485.00 | General |
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $533.87 | General |
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $162.22 | General |
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $132.67 | General |
| 11/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $381.55 | General |
| 11/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $385.92 | General |
| 11/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $160.93 | General |
| 11/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $372.29 | General |
| 11/07/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,040.00 | General |
| Category: COVID-19 | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,090.00 | General |
| Category: COVID-19 | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $752.59 | General |
| Category: COVID-19 | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $78.32 | General |
| Category: COVID-19 | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $1,109.68 | General |
| Category: COVID-19 | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: COVID-19 | ||||||
| 10/16/2024 | PFIZER INC. | ELIQUIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,755.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,572.50 | General |
| 10/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 09/30/2024 | PFIZER INC. | PAXLOVID (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $305.26 | General |
| 09/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $209.30 | General |
| 09/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $182.02 | General |
| 09/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $155.32 | General |
| 09/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $209.30 | General |
| 09/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $209.30 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin: Effectiveness, Safety, and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients with Multimorbidity, Obesity, or Renal Disease | E.R. Squibb & Sons, L.L.C. | $7,150 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 48 | 68 | $31,645 | $6,834 |
| 2021 | 3 | 78 | 120 | $31,143 | $11,033 |
| 2020 | 3 | 55 | 84 | $23,412 | $8,569 |
Total Patients
181
Total Services
272
Medicare Billing
$26,436
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 33 | $13,070 | $2,906 | 22.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $11,711 | $2,314 | 19.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 18 | 18 | $6,864 | $1,614 | 23.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 77 | $17,787 | $6,237 | 35.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $6,720 | $2,417 | 36.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 28 | 28 | $6,636 | $2,379 | 35.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 49 | $11,319 | $4,157 | 36.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 18 | $8,064 | $2,934 | 36.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 17 | 17 | $4,029 | $1,478 | 36.7% |
About Dr. Steven Deitelzweig, MD
Dr. Steven Deitelzweig, MD is a Internal Medicine healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811954910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Deitelzweig, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $153,373 received in 2024. These payments were reported across 672 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($473,750).
As a Medicare-enrolled provider, Deitelzweig has provided services to 181 Medicare beneficiaries, totaling 272 services with total Medicare billing of $26,436. Data is available for 3 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New Orleans, LA
- Active Since 05/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1811954910
Products in Payments
- ELIQUIS (Drug) $643,148
- BEVYXXA (Drug) $48,811
- ANDEXXA (Drug) $23,511
- Veklury (Drug) $22,657
- PAXLOVID (Drug) $12,433
- ANDEXXA (Biological) $4,515
- PRISTIQ (Drug) $4,380
- XARELTO (Drug) $3,920
- RELISTOR (Drug) $833.33
- XIFAXAN (Drug) $833.00
- ATTUNE (Device) $97.70
- PNB AND ACCESSORIES (Device) $58.68
- Veltassa (Drug) $40.11
- ON-Q PUMP AND ACCESSORIES (Device) $13.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New Orleans
Dr. Nassir Marrouche, M.d, M.D
Internal Medicine — Payments: $800,684
Internal Medicine $800,684
Dr. Daniel Johnson, M.d, M.D
Internal Medicine — Payments: $261,660
Internal Medicine $261,660
Sarah Glover, Do, DO
Internal Medicine — Payments: $250,533
Internal Medicine $250,533
Laura Finn, M.d, M.D
Internal Medicine — Payments: $156,942
Internal Medicine $156,942
Dr. Lesley Saketkoo, Md; Mph, MD; MPH
Internal Medicine — Payments: $101,239
Internal Medicine $101,239
Adil Yousuf, Md, MD
Internal Medicine — Payments: $75,842
Internal Medicine $75,842